期刊文献+

冠心病患者活化蛋白C敏感率及抵抗现象的研究 被引量:2

Study on activated protein C sensitivity ratio and activated protein C resistance in patients with coronary heart disease
暂未订购
导出
摘要 目的检测冠心病(CHD)患者活化蛋白C敏感率(APC-SR)并计算活化蛋白C抵抗(APCR)阳性率,探讨APC-SR及APCR在CHD中的临床意义。方法选取2006年1月至7月华中科技大学同济医学院附属协和医院心内科住院的56例CHD患者为研究对象,对照组为同期在本院耳鼻喉科住院的患者54例,采用全自动血凝分析仪测定APC-SR,计算APCR阳性率;同时采用免疫酶联吸附试验检测血浆中蛋白C、总蛋白S和游离蛋白S。结果CHD患者APC-SR平均值(2.44±0.18)显著低于对照组(2.68±0.15)(P<0.01);CHD组APCR阳性率与对照组比较,差异无显著性意义。CHD组APC-SR<2.4的阳性率显著高于对照组(P<0.01)。蛋白C、总蛋白S和游离蛋白S在CHD组和对照组之间差异无显著性意义。结论低水平APC-SR与CHD的发病相关,可考虑将该指标作为CHD危险人群的筛查指标。 Objective To detect activated protein C sensitivity ratio(APC-SR)and prevalence of activated protein C resistance(APCR) in patients with coronary heart disease (CHD)so as to investigate clinical significance of APC-SR and APCR for CHD. Methods Fifty-six patients with coronary heart disease admitted to Department of Cardiology and 54 controls excluded thromboembolic disease, diabetes mellitus and hypertension in Wuhan Union Hospital from January to July 2006 were enrolled. Coronary artery disease group and control group were matched for age, sex and sampling time. APC-SR was measured by full-automated coagulation analyzer( Sysmex CA-7000 ,Japan)and then prevalence of APCR was calculated,plasma levels of protein C, free protein S and total protein S were detected by enzyme-linked immunosorbent assay (ELISA). Results The average APC-SR of C HD patients was significantly lower than that of controls (2.44 ±0.18 versus 2.68 ± 0.15 ,P〈0.001 ) ;there were no significant differences in prevalence of APCR, protein C, free protein S and total protein S between the two groups, and the prevalence of an APC-SR below 2,4 was 39.3% in CHD group, which was significantly higher than that of controls (P〈0.01). Conclusion It is suggested that there is a relationship between low APC-SR and CHD,and APC-SR could be considered as a screening factor for CHD.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第20期1602-1604,共3页 Chinese Journal of Practical Internal Medicine
基金 国家卫生部基金(2004468)
关键词 冠状动脉疾病 活化蛋白C抵抗 蛋白C 蛋白S FV LEIDEN突变 Coronary disease Activated protein C resistance Protein C Protein S Factor V Leiden mutation
  • 相关文献

参考文献13

  • 1李家增.关注动脉血栓栓塞性疾病[J].中华内科杂志,2006,45(1):2-3. 被引量:14
  • 2Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C:prediction of a cofaetor to activated protein C [ J ]. Proc Natl Acad Sci USA, 1993,90 (3) : 1004 - 1008.
  • 3Bertina RM, Kocleman BP, Koster T, et al. Mutation in blood coagulation factor Ⅴ associated with resistance to activated protein C [ J ]. Nature, 1994,369 (6475) :64 - 67.
  • 4Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C [ J ]. J Biol Chem, 1995,270( 36 ) :21158 - 21166.
  • 5Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese[ J ]. Blood, 1998,91 (4) : 1135 - 1139.
  • 6Williamson D, Brown K,Luddington R, et al. Factor V Cambridge: a new mutation (Arg306→Thr)associated with resistance to activated protein C[J]. Blood,1998,91(4) :1140-1144.
  • 7Kabukcu S, Keskin N, Kesdin A, et al. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey [ J ]. Clin Appl Thromb Hemost, 2007, 13 ( 2 ) : 166 - 171.
  • 8马爱华,李牧尧,康福信,托坎.新疆地区汉族和哈萨克族正常人群中FⅤ Leiden突变的初步调查[J].中华血液学杂志,1999,20(5):267-267. 被引量:3
  • 9Wu J, Gu J, Xu J, et al. Factor Ⅴ Leiden mutation in one family of Chinese origin[ J]. Chin Med J,2001,114(4) :379 -381.
  • 10罗佳滨,关月,马洪星,李少英,李月秋,吕学诜.凝血因子V基因点突变1691 A在不同种族人群中的分布[J].中华医学遗传学杂志,1996,13(4):219-220. 被引量:17

二级参考文献29

  • 1Palareti G,Legnani C,Frascaro M,et al.Contraception,1999;59(5):293-299
  • 2Bertina RM,Koelemen BP,Koster T,et al.Nature,1994;369(6475):64-67
  • 3Castaman G,Tosetto A,Simioni M,et al.Thromb Haemost,2001;86(3):804-808
  • 4Tan JY.Ann Acad Med Singapore,2002;31(3):328-334
  • 5Palmieri D,Lee JW,Juliano RL,et al.J Biol Chem,2002;277(43):40950-40957
  • 6Sarig G,Younis JS,Hoffman R,et al.Fertil Steril,2002;77(2):342-347
  • 7Simkova M,Sinko F,Kovacs L.Bratisl Lek Listy,2001;102(5):240-247
  • 8Marcucci R,Bertini L,Giusti B,et al.Thromb Haemost,2001;86(3):772-776
  • 9Hisar I,Ileri M,Yetkin E,et al.Angiology,2000;51(10):855-860
  • 10Kiechl S,Muigg A,Santer P,et al.Circulation,1999;99(5):614-619

共引文献37

同被引文献18

  • 1徐勇,刘雪燕.冠心病、高血压患者活化蛋白C抵抗等凝血物质与血栓前状态的关系研究[J].国外医学(临床生物化学与检验学分册),2004,25(6):494-496. 被引量:4
  • 2芦璐,韩晔,葛汝村.老年高血压患者的血栓前状态分子标志物的改变及临床意义——附100例报告[J].新医学,2006,37(3):157-159. 被引量:8
  • 3Hermans PW, Hazelzet JA. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clin Infect Dis, 2005,41 (Suppl 7) :S453 - S458.
  • 4Kuchenbauer F, Kern W, Schoch C, et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematology,2005,90(12) : 1617-1625.
  • 5Ozeki K, Kiyoi H, Hirose Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood, 2004,103(5) : 1901 - 1908.
  • 6Mosnier LO,Grifin JH. Protein C anticoagulant activity in relation to anti - inflammatory and anti - apoptotic activities. Front Biosci, 2006,11:2381 - 2399.
  • 7Feistritzer C, Riewald M. Endothelial barrier protection by acti rated protein C through PAR1 dependent sphingosine 1 - phosphate receptor - 1 crossactivation. Blood, 2005, 105 (8) 3178 - 3184.
  • 8Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement : role of sphingosine 1 - phosphate receptor transactivation. J Biol Chem, 2005,280(17) : 17286 - 17293.
  • 9Guo H, Liu D, Gelbard H, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron,2004,41(4):563 - 572.
  • 10Liu D, Cheng T, Guo H, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med, 2004,10(12) : 1379 - 1383.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部